特发性膜性肾病免疫抑制治疗的最新研究进展  

Advanced Progress in Immunosuppressive Therapy for Idiopathic Membranous Nephropathy

作　　者：杨艳江 杨向东[1] 

机构地区：[1]山东大学齐鲁医院肾脏内科,山东 济南

出　　处：《临床医学进展》2023年第5期7085-7094,共10页Advances in Clinical Medicine

摘　　要：特发性膜性肾病(Idiopathic membranous nephropathy, IMN)是肾病综合征常见的病因,IMN发病率逐年增加,大约1/3的IMN患者自行缓解,1/3的患者进展为终末期肾脏病,针对高风险的IMN需采取治疗,延缓其进入尿毒症期。目前主要药物包括皮质类固醇激素、烷化剂、钙调磷酸酶抑制剂(他克莫司、环孢素A)、霉酚酸酯、促肾上腺皮质激素、利妥昔单抗及新型抗CD20单克隆抗体。Idiopathic membranous nephropathy (IMN) is one of the most common causes of nephrotic syn-drome, and its incidence rate is increasing year by year, with approximately 1/3 of IMN patients remiss to their own and 1/3 patients progressing to end-stage renal disease, and treatment is needed for high-risk IMN to delay its progression to uremic stage. Current drugs include cortico-steroids, alkylating agents, calcineurin inhibitors (tacrolimus, cyclosporine), mycophenolate mofetil, adrenocorticotropic hormone, rituximab, and anti-CD20 monoclonal antibodies.

关 键 词：特发性膜性肾病 利妥昔单抗 新型抗CD20单克隆抗体 

分 类 号：R69[医药卫生—泌尿科学]